# Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma

> **NCT06751134** · PHASE1 · RECRUITING · sponsor: **Nanjing Children's Hospital** · enrollment: 12 (estimated)

## Conditions studied

- Neuroblastoma, Recurrent, Refractory

## Interventions

- **DRUG:** Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)

## Key facts

- **NCT ID:** NCT06751134
- **Lead sponsor:** Nanjing Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-28
- **Primary completion:** 2026-07-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06751134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06751134, "Chimeric Natural Killer Receptor-Universal T Cells for Relapsed or Refractory Neuroblastoma". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT06751134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*